Drug Detail

Information about BGJ398

Generic Name
IND	BGJ398
Brand Name (US)
Manufacturer	Novartis
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Phase 2
Indications
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block related tumor signal paths + Block tumor blood vessel growth
Drug Category	FGFR inhibitor

BGJ398 (NVP-BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2. (From: Selleckchem)